Trial Profile
A Phase 1b Study of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory Cutaneous T-cell Lymphoma, CD30-positive Peripheral T-cell Lymphoma, or CD30-positive Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 May 2022
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Lenalidomide (Primary)
- Indications Cutaneous T-cell lymphoma; Hodgkin's disease; Peripheral T-cell lymphoma
- Focus Adverse reactions
- Acronyms EpiBrentlen
- 17 May 2022 Status changed from recruiting to completed.
- 29 Sep 2020 Status changed from not yet recruiting to recruiting.
- 09 Oct 2017 New trial record